SBIR/STTR Research Award
Development of peptide nucleic acid antibiotics-supplement 1
Award amount
$3,164,488Program and phase
STTR · Phase IIAward year
2021Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- NUBAD LLC
- Proposal award date
- 2021-02-10
- Contract end date
- 2025-01-31
- UEI
- ENA5G1N2MWP4
- Solicitation number
- PA21-345
- Topic code
- NIAID
Research abstract
This supplement request describes the research and training plan for an underrepresented candidate with background in organic chemistry and an aspiration to become an independent investigator in antimicrobial resistance. The candidate will learn novel chemistries, chemical biology, biophysical techniques, with emphasis on antimicrobial synthesis, development and efficacy determination to identify novel rRNA binding antibacterial therapeutics. The success of the proposed work would be a significant addition to currently available approaches in antibacterial therapy and train a promising candidate in biomedical sciences.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Ototoxicity of modified aminoglycosides
- A biophysical assay targeting SARS CoV-2 RNA
- A biophysical assay targeting Gyrase RNA
- A biophysical assay targeting an essential bacterial gene
- Aminoglycosides with reduced ototoxicity
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Manufacturing and Formulation Process Development for a Prophylactic Cholera Phage Cocktail
- A first-in-class product for the clearance of high-risk human papillomaviruses
- A Rapid, Point-of-Care Diagnostic to Identify Viable Sexually Transmitted Infections, Reduce Overtreatment, and Prevent Emerging Antibiotic Resistance
- Optimization, Pharmacokinetics, and Efficacy of an IgG Protease for the Treatment of Immune Thrombocytopenia and Other IgG-Mediated Autoimmune Diseases
- Nebulized ALX1 as a treatment for Pseudomonas aeruginosa infections in bronchiectasis patients
Research funding history
17 SBIR/STTR records share this UEI (2011–2022). Reported award amounts total $17,738,846. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services